ANTX

SEC source: 0001610717-24-000168 · form4.xml · nonDerivative · entry 1

Eizen Joshua M · CIK 0001949621 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,447

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,207 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023.

F3 · balance_after: Reflects the adjusted total which includes the purchase of 1,240 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023.

SEC source: 0001610717-24-000169 · form4.xml · derivative · entry 2

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-03-14

F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000169 · form4.xml · nonDerivative · entry 1

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,627

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,127 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0001610717-24-000167 · form4.xml · derivative · entry 2

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-03-14

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000167 · form4.xml · nonDerivative · entry 1

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,914

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000166 · form4.xml · derivative · entry 2

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-03-14

F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000166 · form4.xml · nonDerivative · entry 1

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,235

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

F2 · balance_after: Reflects the adjusted total which includes the purchase of 735 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023.

SEC source: 0001610717-24-000165 · form4.xml · derivative · entry 2

Eckburg Paul · CIK 0001914512 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-03-14

F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000165 · form4.xml · nonDerivative · entry 1

Eckburg Paul · CIK 0001914512 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,416

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,127 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023.

SEC source: 0001610717-24-000164 · form4.xml · derivative · entry 5

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,000

Underlying: Common Stock · 198,000 shares

Expires 2034-03-14

F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000164 · form4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,130

F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000194 · form4.xml · nonDerivative · entry 1

Eizen Joshua M · CIK 0001949621 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,447

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000196 · form4.xml · nonDerivative · entry 1

Eckburg Paul · CIK 0001914512 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,416

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000195 · form4.xml · nonDerivative · entry 1

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,627

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000193 · form4.xml · nonDerivative · entry 1

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,914

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000192 · form4.xml · nonDerivative · entry 1

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,235

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000191 · form4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,130

F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

SEC source: 0000950170-24-005900 · ownership.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 405,880

F1 · ownership.nature: These shares are held by Z3 Trust, for which the Reporting Person is a trustee.

SEC source: 0000950170-24-005513 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 377,542

F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-24-005513 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,995,958

F1 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-24-005515 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 377,542

F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-24-005515 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 1,995,958

F1 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0001209191-24-001770 · doc4.xml · nonDerivative · entry 2

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 485,073

F5 · kind: The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023.

F6 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F7 · ownership.nature: Shares held directly by MGC 2018 QP.

SEC source: 0001209191-24-001770 · doc4.xml · nonDerivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 414,788

F1 · kind: The reported sale of 706 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023.

F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.96. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F4 · ownership.nature: Shares held directly by MGC 2018 LP.

SEC source: 0001209191-24-001537 · doc4.xml · nonDerivative · entry 2

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 485,792

F5 · kind: The reported sale of 1,800 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023.

F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F6 · ownership.nature: Shares held directly by MGC 2018 QP.

SEC source: 0001209191-24-001537 · doc4.xml · nonDerivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 415,494

F1 · kind: The reported sale of 1,869 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023.

F2 · price: This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

F4 · ownership.nature: Shares held directly by MGC 2018 LP.

SEC source: 0001610717-24-000027 · form4.xml · derivative · entry 5

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,832

Underlying: Common Stock · 5,000 shares

Expires 2031-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000027 · form4.xml · derivative · entry 4

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,868

Underlying: Common Stock · 2,417 shares

Expires 2030-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F3 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 3

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,914

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 2

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

SEC source: 0001610717-24-000027 · form4.xml · nonDerivative · entry 1

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

SEC source: 0001610717-24-000014 · form4.xml · derivative · entry 3

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,285

Underlying: Common Stock · 2,583 shares

Expires 2030-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F5 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.

SEC source: 0001610717-24-000014 · form4.xml · nonDerivative · entry 2

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,914

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001610717-24-000014 · form4.xml · nonDerivative · entry 1

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.

F2 · balance_after: Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023.

F3 · balance_after: Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023.

SEC source: 0001610717-24-000013 · form4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,130

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2023.

SEC source: 0000950170-23-064611 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 393,449

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-064611 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,080,051

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-064609 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P

Disclosed balance after: 393,449

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-064609 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P

Disclosed balance after: 2,080,051

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051728 · ownership.xml · nonDerivative · entry 4

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 393,737

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051728 · ownership.xml · nonDerivative · entry 3

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,081,573

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 4

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 393,737

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 3

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,081,573

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051728 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 394,639

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051728 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,086,343

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 394,639

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-051733 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,086,343

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050853 · ownership.xml · nonDerivative · entry 4

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P

Disclosed balance after: 410,403

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050853 · ownership.xml · nonDerivative · entry 3

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,169,680

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 4

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P

Disclosed balance after: 410,403

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.